Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
73 hedge funds and large institutions have $23.1M invested in Carisma Therapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 23 reducing their positions, and 24 closing their positions.
0.4% less ownership
Funds ownership: 1.11% → 0.71% (-0.4%)
10% less call options, than puts
Call options by funds: $1.31M | Put options by funds: $1.45M
13% less funds holding
Funds holding: 84 → 73 (-11)
22% less capital invested
Capital invested by funds: $29.5M → $23.1M (-$6.48M)
38% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 24
43% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.53M |
| 2 |
E
Ergoteles
New York
|
+$566K |
| 3 |
Morgan Stanley
New York
|
+$426K |
| 4 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
+$190K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$97.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.32M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.11M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.12M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.08M |
CARM Hedge Fund Activity: Q2 2022 in Review
73 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2022, worth a combined $23.1M — down 22% from $29.5M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CARM and 15 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 13 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.53M. The largest seller was BlackRock, cutting an estimated $5.32M.
- 73 institutional investors held Carisma Therapeutics (CARM) as of Q2 2022, down from 84 in Q1 2022.
- Funds reported $23.1M of Carisma Therapeutics stock for Q2 2022, down 22% quarter-over-quarter.
- 15 funds opened new Carisma Therapeutics positions in Q2 2022 and 24 closed out, a net change of -9 holders.
- The largest Carisma Therapeutics buyer in Q2 2022 was Millennium Management, an estimated $1.53M added.
- The largest Carisma Therapeutics seller in Q2 2022 was BlackRock, an estimated $5.32M sold.
Based on aggregated 13F filings for Q2 2022.